PBI is pleased to announce an excellent rate of accrual of advanced pancreatic cancer patients to their Phase II clinical study.

To date, 37 patients of the target goal of 50 have been entered on the study with no serious adverse events attributable to the investigational drug. Given that our drug is an oral capsule and does not cause debilitating side effects or hair loss, it is an attractive alternative to patients who would rather not have to deal with frequent trips to the hospital for intravenous injections. For these patients, maintaining quality of life is an important consideration. The goal of our PBI-05204 clinical trial is to provide evidence of efficacy and safety in this patient population. To date there is evidence of activity in this heavily pretreated patient population and we are anticipating completion of the trial by the end of the year. The trial is being conducted at five prestigious clinical institutions within the USA.